A5030416477- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Medical Imaging Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
Abstract Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). Patients and Methods: Adults advanced/metastatic NSCLC, acquired resistance to first-/second-generation EGFR inhibitors, gene copy number (GCN) ≥5, MET:CEP7 ≥2, or IHC 2+/3+ were randomized 500 mg (450 active moiety) 250 once daily, chemotherapy. Primary endpoint...
Abstract Introduction: In the INSIGHT trial primary analysis (NCT01982955; median follow-up: 21.8 months), tepotinib (a potent, highly selective, once daily [QD] MET inhibitor) + gefitinib improved efficacy vs chemotherapy (CTX) in patients with EGFR-mutant NSCLC and resistance to anti-EGFR therapy due amplification (Wu et al, Lancet Respir Med 2020). Here we report final analyses from (data cut-off: September 3, 2021; 57.5 months). Methods: Patients (T790M-negative) resistance, gene copy...
<p>Plain language summary</p>
<p>Treatment-related adverse events in treated patients with MET amplification and/or IHC 2+/3+</p>
<p>Outcomes of treatment for the patient subgroup with MET overexpression</p>
<p>Duration of PFS in the patient subgroup with MET amplification</p>
<p>Outcomes of treatment for all individuals enrolled</p>
<p>Outcomes of treatment for all individuals enrolled</p>
<p>Treatment-related adverse events in treated patients with MET amplification and/or IHC 2+/3+</p>
<p>Outcomes of treatment for the patient subgroup with MET overexpression</p>
<p>Plain language summary</p>
<p>Duration of PFS in the patient subgroup with MET amplification</p>
<div>Abstract<p>Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). Patients and methods: Adults advanced/metastatic NSCLC, acquired resistance to first-/second-generation EGFR inhibitors, gene copy number (GCN) ≥5, MET:CEP7 ≥2, or IHC 2+/3+ were randomized 500 mg (450 active moiety) 250 once daily,...
<p>Outcomes of treatment for all individuals enrolled</p>
<div>AbstractPurpose:<p>The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with <i>MET</i>-altered <i>EGFR</i>-mutant NSCLC (data cut-off: September 3, 2021).</p>Patients and methods:<p>Adults advanced/metastatic NSCLC, acquired resistance to first-/second-generation EGFR inhibitors, <i>MET</i> gene copy number (GCN) ≥5,...
<p>Duration of PFS in the patient subgroup with MET amplification</p>